Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed uveal melanoma * Metastatic disease * Measurable disease, defined as ≥ 1 measurable lesion as measured by RECIST criteria * No curative surgical treatment envisaged * No active brain metastases (if clinical suspicion, must have a brain CT scan within 28 days) PATIENT CHARACTERISTICS: * WHO performance status (PS) 0-1 OR Karnofsky PS 70-100% * Life expectancy ≥ 12 weeks * Hemoglobin ≥ 10 g/dL * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Serum creatinine ≤ 1.5 times upper limit of normal (ULN) OR calculated creatinine clearance ≥ 50 mL/min * Proteinuria \< 2+ on urinary dipstick OR 24-hour proteinuria ≤ 1 g * Total bilirubin ≤ 1.5 times ULN * AST/ALT ≤ 2.5 times ULN * Lactate dehydrogenase ≤ 5 times ULN * INR and PT ≤ 1.5 times ULN * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after completion of study treatment * No uncontrolled active disease or at risk of bleeding, ongoing infection, or clotting disorder * No other cancer except for skin carcinomas and cervical carcinoma in situ * No pre-existing peripheral neuropathy, \> grade 2 (NCI CTC-AE) * No failure to comply with the medical follow-up of the study for geographical, social, or psychological reasons * No recent thrombophlebitis or pulmonary embolism within the past 6 months * No uncontrolled hypertension (systolic BP \> 150 mm Hg and/or diastolic BP \> 100 mm Hg) * No concurrent active cardiovascular disease, uncontrolled by medical treatment within the past 6 months, including any of the following: * Unstable angina * Severe hypertension * Severe arrhythmia * No unhealed wound, active peptic ulcer, bone fracture, history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * No known hypersensitivity to bevacizumab, temozolomide, or their excipients PRIOR CONCURRENT THERAPY: * No prior chemotherapy for metastatic disease * At least 24 hours since insertion of central infusion port * More than 5 days since prior non-hepatic biopsy or aspiration cytology * More than 10 days since prior aspirin (\> 325 mg/day), clopidogrel (\> 75 mg/day), or full-dose oral or parenteral anticoagulant therapy, except prophylactic anticoagulant therapy prior to inclusion in the study * More than 14 days since prior laparoscopic liver biopsy * More than 28 days since prior major surgery * More than 28 days since prior participation in another study with experimental treatment * No other concurrent anticancer treatment